Triptolide is a bioactive ingredient in traditional Chinese medicine that exhibits diverse biological properties, including anticancer properties. Among its many putative targets, this compound has been reported to bind to XPB, the largest subunit of general transcription factor TFIIH, and to cause degradation of the largest subunit Rpb1 of RNA polymerase II (RNAPII). In this study, we clarify multiple important questions concerning the significance and basis for triptolide action at this core target.
Abstract
Triptolide is a bioactive ingredient in traditional Chinese medicine that exhibits diverse biological properties, including anticancer properties. Among its many putative targets, this compound has been reported to bind to XPB, the largest subunit of general transcription factor TFIIH, and to cause degradation of the largest subunit Rpb1 of RNA polymerase II (RNAPII). In this study, we clarify multiple important questions concerning the significance and basis for triptolide action at this core target.
Triptolide decreased Rpb1 levels in cancer cells in a manner that was correlated tightly with its cytotoxic activity. Compound exposure blocked RNAPII at promoters and decreased chromatin-bound RNAPII, both upstream and within all genes that were examined, also leading to Ser5 hyperphosphorylation and increased ubiqutination within the Rbp1 carboxy-terminal domain. Notably, co-treatment with inhibitors of the proteasome or the cyclin-dependent kinase CDK7 inhibitors abolished the ability of triptolide to ablate Rpb1. Together, our results show that triptolide triggers a CDK7-mediated degradation of RNAP II that may offer an explanation to many of its therapeutic properties, including its robust and promising anticancer properties.
Introduction
Triptolide is a principal bioactive ingredient of Tripterygium wilfordii Hook F, which has been used to treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and psoriasis in China (1) . In addition to its unique structure of a diterpenoid triepoxide, triptolide has aroused extensive research interests due to the following pharmacological characteristics. Triptolide possesses multiple apparently-unrelated activities including anti-inflammatory, immunosuppressive, anti-fertility, anti-cystogenesis and anticancer activities (1), which appears to suggest multiple molecular mechanisms involved in. Moreover, according to a comparative analysis by using the NCI-60 internal database, the GI50 profile of triptolide is significantly different from those of 118 reference anticancer compounds (2) , suggesting that triptolide could have anticancer mechanisms and molecular targets potentially distinct from those of other anticancer agents. Consistent with its various activities, triptolide has been revealed to interact with several cellular proteins, including polycystin-2 (PC-2), disintegrin and metalloprotease 10 (ADAM10), dCTP pyrophosphatase 1 (DCTPP1) and XPB (1) . These proteins with distinct functions have thus been identified as its potential primary targets. And possibly, more potential targets would be added to the list in future because using the known targets of triptolide cannot fully explain its activities. Triptolide inhibits RNA polymerase II (RNAPII)-dependent transcription, showing a distinct mode of action 4 The effect of triptolide on transcription has been paid special attention to in recent years because this effect appears to contribute to most of its biological activities, in particular, anticancer, anti-inflammatory and immunosuppressive activities (1) . Triptolide affects mRNA transcription in a concentration-and timedependent manner. Treatment with triptolide at low concentrations and/or short exposure largely inhibits the transcription of short-lived mRNA, and possibly as a compensatory response, increases the transcription of some other genes such as p53.
In contrast, its high concentrations and persistent exposure could reduce 80% mRNA transcription (2) . Two factors, XPB inhibition and RNAPII degradation induced by triptolide, have been proposed to be responsible for its transcriptional inhibition (1, 6) .
XPB, a subunit of the general transcription factor TFIIH, is involved in both RNAPIImediated transcription initiation and DNA nucleotide excision repair (NER) (7) .
Triptolide directly binds to XPB, inhibits its ATPase activity and consequently, represses RNAPII transcription initiation and NER (4, 6) . The previous reports revealed that inhibition of both XPB activity and mRNA transcription required only low concentrations of and/or short exposure to triptolide but induction of RNAPII degradation needed relatively high concentrations of and/or long exposure to the drug (2, 4, 6) . Those data appear to suggest that RNAPII degradation induced by triptolide could contribute to its transcriptional inhibition at a relatively later stage but to a relatively more severe degree than XPB inhibition. Therefore, clarifying the molecular mechanism (s) of RNAPII degradation induced by triptolide would be critical to fully understanding its transcriptional inhibition.
Degradation of RNAPII often follows ubiquitination of its largest subunit, Rpb1 (8) (9) (10) . Ubiquitination can occur at different sites, both on the carboxy-terminal domain (CTD) (11) and other residues (12) , which depends on the type of transcriptional stress or stalling. The CTD consists of multiple repeats of the consensus sequence Y 1 S 2 P 3 T 4 S 5 P 6 S 7 , plays a fundamental role in regulating the RNAPII-mediated transcription and the stability of Rpb1 (8, 13, 14) . Phosphorylation at Ser-5 and Ser-2 of the CTD regulates transcription initiation and elongation, respectively, at specific steps (14, 15) . Ser-5 phosphorylation is mainly catalyzed by cyclin-dependent kinase 7 (Cdk7), a subunit of the general transcription factor TFIIH, which occurs in early phases of transcription initiation and allows promoter clearance of RNAPII. In contrast, Ser-2 is mainly phosphorylated by the positive transcriptional elongation factor (PTEF-b; the CDK9/CyclinT1 complex), which promotes transcriptional elongation (14) . Based on the inconsistent data from different experimental approaches in the previous reports (8, 10, (16) (17) (18) , however, whether phosphorylation of the CTD is correlated with ubiquitination and RNAPII degradation remains controversial and has to be clarified.
In terms of triptolide, particularly, although Rpb1 degradation by this agent has been consistently reported, whether it elicits phosphorylation of the CTD also seems controversial (3, 4, 6) . In addition, though the inability to recruit TFIIH has been shown to induce RNAPII stalling at promoters (19, 20) , whether triptolide could induce a RNAPII stalling at active promoter regions remains to be established.
Moreover, XPB inhibition by triptolide is known to suppress transcription initiation (4) and as known, only a fraction of the total RNAPII binds to template DNA and engages in transcription (10) . However, whether triptolide-induced Rpb1 degradation affects the chromatin-bound RNAPII is yet to be investigated. contributed to its RNAPII degradation. We further found that the chromatin-bound reduction of Rpb1 at promoters was subsequent to a block of RNAPII at promoterproximal sites of transcribed genes. Our data also showed that the Rpb1 degradation was associated with the cell-killing potency of triptolide, indicating the biological importance of the triptolide-driven, CDK7-mediated Rpb1 degradation.
Materials and Methods
Reagents. Triptolide used in our experiments was prepared from Tripterygium wilfordii Hook F as described previously (21) . MG132, epoxomicin, cycloheximide (CHX), DRB and H-7 were purchased from Sigma. Triptolide (10 mM), MG132 (10 mM), epoxomicin (10 mM), CHX (50 mg/mL), and DRB (50 mM) were dissolved in dimethyl sulfoxide (Sigma) as stock solutions, respectively; H-7 (50 mM) was dissolved in ethanol. The stock solutions were kept in aliquot at -20°C (triptolide, epoxomicin, CHX, DRB and H-7) or at -80°C (MG132) and thawed immediately prior to each experiment. RPB1 (CTD repeat), phospho-Ser-2-RPB1, phospho-Ser-5-RPB1 and ubiquitin antibodies were from Abcam, CDK7 and β-actin antibodies were from Cell Signaling Technology, RPB1 (H-224) antibody was from Santa Cruz Biotechnology, and GAPDH antibody was from Beyotime, China. Statistical analyses. Data were presented as mean ± SD, and statistical significance was assessed with the Student's t test. Differences were considered significant at P < 0.05.
Results
Phosphorylation at Ser-5 of the CTD is an early molecular event prior to Rpb1 reduction induced by triptolide. To confirm whether triptolide can induce reduction of Rpb1 as reported (2, 4, 6) and to clarify its kinetics, we treated human ovarian (Fig. 1A) . In response to the similar treatment, interestingly, the levels of phosphorylation at Ser-5 of the CTD first rose before 15 min, reached their maximum at 30 min, and then began to decrease in SK-OV-3 cells (Fig. 1B) .
The result was repeatable in PC-3 cells when exposed to a lower concentration of triptolide (100 nM) for longer times (Fig. 1C) . At the same condition, however, the levels of phosphorylation at Ser-2 remained unchanged in both SK-OV-3 and PC-3 cells and the levels of Rpb1 itself reduced persistently (Figs. 1B and 1C) . The data suggest that the selective induction of phosphorylation at Ser-5 of the CTD could be an early molecular event prior to the Rpb1 decrease, and the latter is possibly responsible for the subsequent reduction of the phosphorylated Rpb1 at Ser-5 in the triptolide-treated cancer cells.
The tumor cell-killing activity of triptolide correlates with its RNAPII decrease.
In order to determine whether the effect of triptolide on RNAPII is a critical event for cytotoxic activity, we detected by Western blotting and observed the differential degradation of the cellular Rpb1 protein in a panel of cancer cell lines exposed to gradient concentrations of triptolide for 6 h ( Fig. 1D and Suppl. anticancer activity.
Triptolide-induced Rpb1 decrease involves a Cdk7-mediated proteasomedependent protein degradation mechanism. As a general transcriptional inhibitor, triptolide can lead to reduction of cellular mRNA (2, 4). So we assessed whether the observed decrease of Rpb1 was attributable to downregulation of its mRNA levels.
RT-PCR analyses by using different amplicons along the Rpb1 mRNA sequence clearly revealed that Rpb1 mRNA levels did not change significantly in SK-OV-3 cells exposed to triptolide (Fig. 2A) . Moreover, the triptolide-induced decrease of Rpb1 was independent of its new protein synthesis, as shown by co-treatments with the protein synthesis inhibitor cycloheximide (CHX; Fig. 2B ), excluding the possibility that the Rpb1 decrease resulted from its reduced protein synthesis. Instead, the inhibition of proteasomal activity with either epoxomicin (Fig. 2C) or MG132 (Suppl. Fig. 2A ) reversed the triptolide-induced decrease of Rpb1, showing that the latter involves a proteasome-dependent protein degradation mechanism. And as expected, the treatment with 1 μM triptolide for 20 min led to increased hyperphosphorylation at Ser-5 and ubiquitination of Rpb1 in SK-OV-3 cells (Fig. 2D) .
The von Hippel-Lindau tumor suppressor protein VHL and the tumor suppressor BRCA1 have been reported to ubiquitinate Rpb1 (11, 24) . However, the triptolideinduced degradation of Rpb1 appeared to be independent of either of them because 
inhibit Cdk7 and Cdk9 with about 3-fold lower efficiency for the former, but H7 could inhibit both of them almost equally (3, 25) . Our results revealed that at low concentrations (≤100 nM) of triptolide, DRB completely prevented the Rpb1 degradation, but at a high concentration (1000 nM) of triptolide, DRB rescued Rpb1 just partially. In contrast, H7 totally prevented the Rpb1 decrease triggered by triptolide at all tested concentrations (10 nM-1000 nM) (Fig. 2E) . Together with the Rpb1 phosphorylation at Ser-5 rather than at Ser-2 induced by triptolide, the effects of both DRB and H7 suggest that triptolide could selectively cause the activation of Cdk7, which is likely to mediate the triptolide-induced Rpb1 degradation.
Triptolide-induced block of RNAPII at promoters precedes chromatin-bound enzyme reduction. The above results show a potential correlation of cellular RNAPII decrease with the phosphorylation at Ser-5 and ubiquitination of Rpb1 and its proteasome-dependent degradation induced by triptolide. However, we did not know whether these effects of the drug indeed affected the engagement of RNAPII in transcription. Ser-5-hyperphosphorylated RNAPII is known to be mainly located near gene promoter regions (13) . Therefore, we first performed ChIP assays by using an antibody against the N-terminal domain of RNAPII in the PC-3 cells treated with triptolide to see whether the chromatin-bound RNAPII at the promoter regions of transcribed genes reduces. The data revealed that 2-h treatments with 1 µM triptolide resulted in a depletion of more than 90% of the RNAPII bound to the promoters of transcribed myc, hif-1α, vegf and polr2a genes (Fig. 3A) . Time course experiments with a lower drug concentration (100 nM) further showed the significant decrease of RNAPII at those promoters after 3 h (Fig. 3B) . Interestingly, 100 nM triptolide did not reduce, and even increased in some cases, the RNAPII density at the tested promoters at 2 h (Fig. 3B) CAN-12-1006 of the RNAPII density at those class II gene promoters in a concentration-and timedependent manner, in agreement with the RNAPII depletion detected in cellular extracts (Fig. 1) .
In addition to protein degradation, reduction of the RNAPII density at promoters could also result from an increased escape of RNAPII from promoter-proximal pausing sites as in the case of camptothecin (22, 26). To exclude this possibility, we performed ChIP assays to detect the distribution of RNAPII at different sites along transcribed genes at different time points in PC-3 cells treated with 100 nM triptolide.
Triptolide induced a reduction of RNAPII at both promoters and exons in all the tested genes (Fig. 4) . However, the reduction kinetics was significantly different at the promoters and the exons of those genes. At all the tested promoters, the decrease of the RNAPII density was not detectable at 1-and 2-h time points though apparent after the 3-h treatment; in contrast, the levels of RNAPII bound to the corresponding exons were markedly reduced at all the examined time points (1 h -4 h) (Fig. 4) .
Interestingly, we detected a significant increase of RNAPII at c-myc promoter following 1 h of treatment, while a consistent polymerase decrease was found at the gene exons (Fig. 4A) . Similar results were found at the other two genes, vegf and hif-1α, at the promoters of which RNAPII density was substantially unaltered after 1 h -2 h of treatments, while it was consistently decreased at exons. After longer drug treatments, RNAPII was reduced also at promoter regions (Fig. 4) .
Thus, our present findings show that triptolide can first induce a block of RNAPII at the promoters of active genes. Moreover, chromatin-bound RNAPII can then be degraded likely due to the hyperphosphorylation at Ser-5. The degradation of chromatin-bound RNAPII can likely explain the reduction of cellular mRNA levels following triptolide treatments as reported previously (2, 4, 6 Cdk7 mediates the triptolide-induced RNAPII degradation. In order to demonstrate the role of Cdk7 and Ser-5 hyperphosphorylation in the degradation of total and chromatin-bound RNAPII, we used specific siRNA to interfere with the expression of Cdk7 in PC-3 cells. Western blotting analyses on cellular protein extracts showed that downregulation of Cdk7 with its siRNA prevented the hyperphosphorylation of Rpb1 at its Ser-5 and its subsequent degradation induced by triptolide (Fig. 5A) . Similarly, Cdk7 siRNA also apparently protected the RNAPII bound to the promoters of transcribed myc, hif-1α, vegf and polr2a genes from degradation (Fig. 5B ). The results demonstrate that the Cdk7-dependent phosphorylation of Rpb1 at Ser-5 of its CDT is required for triptolide-triggered degradation of both the total RNAPII and the RNAPII bound to the promoters of the transcribed genes.
Discussion
The transcription factor TFIIH consists of 10 subunits including XPB and Cdk7 (27). TFIIH is a basal factor functioning at the stages of transcription initiation, promoter escape and early elongation. XPB with its DNA-dependent ATPase activity opens the DNA around the transcription start site and Cdk7 by its kinase activity phosphorylates Rpb1 at Ser-5 of the CTD. Both are required for transcription initiation (27, 28). Previously, triptolide was reported to covalently bind to XPB and inhibit its ATPase activity, resulting in the inhibition of RNAPII-driven transcription (4) . Here we further indicate that Cdk7 mediates triptolide-induced Rpb1 degradation via increasing its phosphorylation at Ser-5.
In our current study, we demonstrated that triptolide induced cellular RNAPII ability of the drug was proportionally correlated with its tumor cell-killing activity (Fig. 1D) . Moreover, the results indicate that RNAPII is not reduced at promoters up to 2 h of treatments (rather it is increased in the case of c-myc), whereas it is reduced at all the exons examined for the same time periods. Thus, we can suggest that RNAPII block at promoters is an early event induced by triptolide (Figs. 3-5 ).
These effects confer apparent biological significance to further exploration on the potential molecular mechanism. Triptolide was shown to lead to the Rpb1 hyperphosphorylation at Ser-5 rather than at Ser-2 and the increased Rpb1 Rpb1 but not antibodies against Rpb1 phosphorylated at specific sites. Therefore, their results did not directly reveal the site where the hyperphosphorylation of Rpb1 took place, although they used DRB and H7, both of which are able to inhibit more than one kinases including CDK7 and CDK9 (3, 25) , to indirectly infer that Ser-2 of the CTD could be the site. In contrast, our study used specific antibodies respectively against Rpb1 phosphorylated at Ser-2 and at Ser-5 to clearly show that the site is Ser-5 rather than Ser-2. At the same time, our data demonstrated the biphasic kinetics of triptolide-induced Rpb1 hyperphosphorylation at Ser-5 (Figs. 1B, 1C and 2D ). Wang et al further used CDK9 siRNA and Cyclin T1 siRNA in their report. However, it is hard to conclude that these siRNAs indeed prevented the triptolide-induced Rpb1 hyperphosphorylation due to the poor quality of Rpb1 Western blotting images (6). In our current study, our data revealed that Cdk7 siRNA prevented the Ser-5 hyperphosphorylation of Rpb1 caused by triptolide (Fig. 5A) . Thus, our results clearly indicate that triptolide gives rise to the Cdk7 activation that mediates the Rpb1 hyperphosphorylation at Ser-5. However, we cannot fully exclude that Cdk9 can contribute to the hyperphosphorylation of Rpb1 as it has also been shown to phosphorylate the CTD at Ser-5 of Rpb1 in vitro (29).
Our study further indicates that the pharmacological inhibitors and siRNA of Cdk7 can reverse the proteasome-dependent degradation of the cellular and chromatin-bound Rpb1 induced by triptolide (Figs. 2E and 5 ). This finding shows that the CTD plays a role in maintaining Rpb1 stability, and can further help to clarify the other controversial issue of whether phosphorylation of the CTD is correlated with its ubiquitination and Rpb1 degradation (8, 10, 16, 17 (Fig. 6, upper panel; http://www.ncbi.nlm.nih.gov/ nuccore/306482654). This is interesting because there is not only a lysine residue at the 7 position but also a serine residue at the 5 position of those sequences except the last one. These sites are likely to be the potential targets of the E3 ligase for polyubiquitination (Lys7) (30) and Cdk7 for phosphorylation (Ser-5). TFIIH concomitantly possesses these two activities of the kinase for Ser-5 phosphorylation and the E3 ligase attributing to its subunits of Cdk7 and p44, respectively (30, 31). Moreover, triptolide has been shown to bind to the XPB subunit, but not to other subunits of TFIIH (4) . Together with our data in this study, we therefore propose a possible mechanism by which triptolide causes Rpb1 degradation and transcriptional inhibition (Fig. 6, lower panel) . The binding of triptolide to XPB might, via unknown mechanism(s) (probably via the change in the conformation of the complex as the XPB homolog structure implies a major conformational change upon ATP binding) (32), activate Cdk7 and p44. The activated Cdk7 could lead to the Ser-5 phosphorylation at the standard heptapeptide consensus sequence of Y1S2P3T4S5P6S7 and the heptapeptide variants of Y1S/T2P3T4S5P6K7. The former might cause RNAPII stalling and, the latter might facilitate the polyubiquitination mediated by the activated p44, which could be potentiated by the RNAPII stalling.
The ubiquitination of Rpb1 results in its proteasome-dependent degradation. As we did not determine the acceptor sites of the ubiquitin chain in Rbp1 in response to triptolide treatments, we cannot exclude the possibility that Rbp1 is ubiquitinated outside from the CTD. It could be possible that the binding of triptolide to XPB and the RNAPII stalling elicit immediate or early transcriptional inhibition, and the subsequent persistent inhibition results from the decrease of RNAPII due to the Rpb1 degradation. 
The proposed mechanism could reasonably unify all the Ser-5 hyperphosphorylation, ubiquitination-mediated Rpb1 degradation and RNAPII-driven transcriptional inhibition induced by triptolide into one primary target XPB and one related complex TFIIH. Our findings show that triptolide is a transcriptional inhibitor unique and distinct from all other known transcriptional inhibitors including DRB, flavopiridol, actinomycin D and α-amanitin (3, 4, 33) . Thus, triptolide could serve as an exquisite tool to further investigate the regulation and function of TFIIH, and act as a model compound for anticancer/other drug development specifically targeting the transcription factor TFIIH. 
